Catalyst Pharmaceuticals, Inc. (CPRX)

In November 2025, Catalyst Pharmaceuticals participated in Citi's 2025 Global Healthcare Conference and was recognized as one of North America's Fastest-Growing Companies. In December 2025, the company participated in the 44th Annual J.P. Morgan Healthcare Conference. In January 2026, Catalyst Pharmaceuticals was ranked on Forbes' 2026 List of America's Most Successful Small-Cap Companies and hosted the inaugural Catalyst Advocacy Scholars Summit. In February 2026, the company reported record fourth-quarter and full-year 2025 financial results and provided 2026 financial guidance, leading to a +2.77% change in stock price. In March 2026, Catalyst Pharmaceuticals showcased real-world findings in Duchenne muscular dystrophy and hosted a Vamorolone-focused symposium, and Citi raised the company's price target to $35. In April 2026, the 10-day moving average for CPRX crossed bullishly above the 50-day moving average, Catalyst Pharmaceuticals secured extended U.S. patent exclusivity for Firdapse until 2035, and launched Agamree.

Information regarding specific demand seasonality for Catalyst Pharmaceuticals, Inc.'s products and services is limited. One source indicates a "Seasonality Score: -11" without further elaboration. The biopharmaceutical industry, particularly for rare diseases, may experience less pronounced seasonality compared to consumer goods, as demand is driven by ongoing medical needs rather than seasonal trends. Factors such as new product launches, clinical trial results, regulatory approvals, and patent expirations tend to have a more significant impact on revenue and stock performance.

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for rare and challenging-to-treat diseases. The company's primary products include Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, Ruzurgi for pediatric LEMS patients, Fycompa for seizures, and AGAMREE for Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

Catalyst Pharmaceuticals has a strong commercial presence in the United States and is exploring global expansion opportunities. Firdapse is available in Canada and Japan through a sub-licensee. AGAMREE has been submitted to Health Canada for Priority Review, potentially becoming the first approved DMD treatment in Canada by the end of 2025. The company's headquarters are located in Coral Gables, Florida.

Catalyst Pharmaceuticals has a positive brand reputation within the rare disease biopharmaceutical industry. The company was recognized on Forbes' 2026 List of America's Most Successful Small-Cap Companies. Analysts generally hold a favorable view, with a consensus "Buy" rating and a predicted upside of 35.84%. The company emphasizes its dedication to patient care and accessibility, offering support services to ensure patients receive necessary care.

Catalyst Pharmaceuticals has a diverse ownership structure, with institutional investors holding approximately 82% to 85.12% of shares. As of April 9, 2026, 376 institutional owners and shareholders held a total of 104,057,316 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Major individual owners include Biomarin Pharmaceutical Inc, Patrick J. McEnany, and Hubert E. Huckel.